WO2014015874A1 - A dressing product and a cosmetic or medical composition with kigelia africana - Google Patents
A dressing product and a cosmetic or medical composition with kigelia africana Download PDFInfo
- Publication number
- WO2014015874A1 WO2014015874A1 PCT/DK2012/050280 DK2012050280W WO2014015874A1 WO 2014015874 A1 WO2014015874 A1 WO 2014015874A1 DK 2012050280 W DK2012050280 W DK 2012050280W WO 2014015874 A1 WO2014015874 A1 WO 2014015874A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- africana
- dressing product
- cosmetic
- medical composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 239000002537 cosmetic Substances 0.000 title claims abstract description 33
- 235000002329 Kigelia pinnata Nutrition 0.000 title claims abstract description 16
- 244000062767 Kigelia africana Species 0.000 title claims abstract 11
- 239000000284 extract Substances 0.000 claims abstract description 94
- 239000004480 active ingredient Substances 0.000 claims abstract description 54
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 claims abstract description 41
- 239000012267 brine Substances 0.000 claims abstract description 40
- 238000000034 method Methods 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 21
- 239000003349 gelling agent Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 6
- 239000003921 oil Substances 0.000 claims abstract description 6
- 230000037380 skin damage Effects 0.000 claims abstract description 6
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 239000006096 absorbing agent Substances 0.000 claims abstract description 5
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 5
- 235000006708 antioxidants Nutrition 0.000 claims abstract description 5
- 239000011230 binding agent Substances 0.000 claims abstract description 5
- 239000003974 emollient agent Substances 0.000 claims abstract description 5
- 239000000945 filler Substances 0.000 claims abstract description 5
- 239000003906 humectant Substances 0.000 claims abstract description 5
- 239000003755 preservative agent Substances 0.000 claims abstract description 5
- 230000000475 sunscreen effect Effects 0.000 claims abstract description 5
- 239000000516 sunscreening agent Substances 0.000 claims abstract description 5
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 239000000375 suspending agent Substances 0.000 claims abstract description 5
- 239000002562 thickening agent Substances 0.000 claims abstract description 5
- 230000001070 adhesive effect Effects 0.000 claims description 66
- 239000000853 adhesive Substances 0.000 claims description 65
- 239000000416 hydrocolloid Substances 0.000 claims description 65
- 239000007788 liquid Substances 0.000 claims description 30
- 239000000499 gel Substances 0.000 claims description 25
- 239000011888 foil Substances 0.000 claims description 20
- 239000006071 cream Substances 0.000 claims description 19
- 239000002904 solvent Substances 0.000 claims description 18
- 201000004681 Psoriasis Diseases 0.000 claims description 16
- 201000004624 Dermatitis Diseases 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 238000005516 engineering process Methods 0.000 claims description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- 239000012943 hotmelt Substances 0.000 claims description 9
- 238000005507 spraying Methods 0.000 claims description 9
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 229920006254 polymer film Polymers 0.000 claims description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 6
- 235000010493 xanthan gum Nutrition 0.000 claims description 6
- 239000000230 xanthan gum Substances 0.000 claims description 6
- 229920001285 xanthan gum Polymers 0.000 claims description 6
- 229940082509 xanthan gum Drugs 0.000 claims description 6
- NLMKTBGFQGKQEV-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-hexadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO NLMKTBGFQGKQEV-UHFFFAOYSA-N 0.000 claims description 3
- ICIDSZQHPUZUHC-UHFFFAOYSA-N 2-octadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCO ICIDSZQHPUZUHC-UHFFFAOYSA-N 0.000 claims description 3
- HXVCOQUDJKMJQY-UHFFFAOYSA-N 2-octyldodecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC HXVCOQUDJKMJQY-UHFFFAOYSA-N 0.000 claims description 3
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 3
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 3
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 3
- 229960000458 allantoin Drugs 0.000 claims description 3
- 239000007765 cera alba Substances 0.000 claims description 3
- 229940056318 ceteth-20 Drugs 0.000 claims description 3
- 229960000541 cetyl alcohol Drugs 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- PKPOVTYZGGYDIJ-UHFFFAOYSA-N dioctyl carbonate Chemical compound CCCCCCCCOC(=O)OCCCCCCCC PKPOVTYZGGYDIJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 229940057910 shea butter Drugs 0.000 claims description 3
- 229940100459 steareth-20 Drugs 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 244000014603 Kigelia pinnata Species 0.000 description 75
- 210000003491 skin Anatomy 0.000 description 54
- 239000010410 layer Substances 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 26
- 230000000694 effects Effects 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 235000002639 sodium chloride Nutrition 0.000 description 12
- 241000196324 Embryophyta Species 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 8
- 239000007921 spray Substances 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 230000002045 lasting effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 235000010755 mineral Nutrition 0.000 description 5
- 230000008092 positive effect Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000009792 diffusion process Methods 0.000 description 4
- 239000003673 groundwater Substances 0.000 description 4
- 239000013535 sea water Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920002367 Polyisobutene Polymers 0.000 description 2
- 239000012790 adhesive layer Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000001694 spray drying Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000003014 Bites and Stings Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 244000018951 Cordia abyssinica Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000001540 jet deposition Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- -1 other than NaCI Chemical class 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 229920006264 polyurethane film Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0208—Tissues; Wipes; Patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a dressing product comprising an ex- tract of Kigelia africana, and to a method of producing the dressing product.
- the invention also relates to a cosmetic or medical composition for topical application on the skin of a subject, which composition comprises an extract of K. africana.
- the dressing product and the composition are suitable for use in the treatment of skin damages, diseases and conditions.
- the dressing product and the composition provide a longer lasting effect of the activities of K. africana.
- WO 2006/002443 describes pharmaceutical and cosmetic preparations based on K. africana.
- the preparations of WO 2006/002443 may be in the form of a cream, ointment or gel, and it is intended as a general pain reliever, an anti-septic, an anti-inflammatory or an anti-pruritic.
- Specific applications are for the treatment of cuts, bruises, insect bites, stings, sun exposure of the skin, psoriasis, eczema, solar keratosis, and cancerous sores.
- FR 2 759 910 also describes cosmetic compositions for skin care and body care containing extracts of K. africana. The may be used for firming of the bust, limiting hair loss, and limiting hair growth. Further skin creams of K. africana are provided by ZW 10292.
- Kigelia africana (Lam.) Benth - An overview, S. Saini, H. Kaur, B. Vherma, Ripudaman, S. K. Singh, 2009, Nature Product Radiance, 8: 190-197, and Comprehensive scientific demystification of Kigelia africana : A review, Olatunji A. Gabriel and Atolani Olubunmi, 2009, African Journal of Pure and Applied Chemistry, 3: 158-164. Saini et al., 2009, describe how an ethanol extract was tested for pharmacological activity in animal studies in mice and in cell lines. It was concluded from the tests that ethanolic extracts of K. Africana have a significant positive effect on use against skin irritation / oedema and a significant antibacterial/ antimicrobial inhibitory effect on both Gram-positive and Gram-negative bacteria
- a first aspect the present invention relates to a dressing product comprising a backing layer and an active ingredient layer comprising an extract of Kigelia africana, which active ingredient layer is coated or adhered to the backing layer.
- the extract e.g. an ethanolic extract, from K. Africana, e.g. the fruit, shows a significant effect on treatment skin diseases and conditions, such as psoriasis, eczemas, dermatitis and acne.
- the dressing product of the invention is suitable for application to the skin of a subject, e.g. a human subject, in order to provide the effect of the K. africana extract to the skin of the subject.
- the active ingredient layer may comprise an adhesive, preferably a hydrocolloid adhesive, allowing the dressing product to adhere to the skin of the subject.
- Hydrocolloid adhesives provide excellent adhesive properties to the skin of subject, so that the dressing sticks efficiently.
- the hydrocolloid adhesive will serve as a carrier for the K. africana extract and allowing the active compounds of K. africana to diffuse to the skin of the subject.
- the hydrocolloid adhesive absorbs moisture from damaged skin forming a liquid gel over the damaged skin resulting in delivery of the K. africana extract to the damaged skin.
- the active ingredient layer especially in the form of a hydrocolloid adhesive, provides that the K. africana extract is kept in place on the skin.
- the combined effects of the stickiness of the hydrocolloid adhesive, and the aqueous nature, i.e. the "gel effect" allow a long-term diffusion of the active compounds of K. africana to the skin of the subject where the dressing product is applied.
- Such a long-term effect cannot readily be obtained when the K. africana extract is applied directly to the skin or via a dressing not comprising a hydrocolloid adhesive.
- Any hydrocolloid adhesive may be employed for the dressing of the invention.
- the backing layer may be any suitable material, such as a polymer film or film of non-woven polymer fibres.
- the polymer film may be permeable to gasses, e.g. to allow diffusion of water molecules from the skin or the dressing product, or to allow diffusion of oxygen from the surroundings to the skin.
- the polymer film may also be non-permeable.
- a preferred polymer material is polyurethane.
- the active ingredient layer is coated on or adhered to the backing layer to form the dressing product.
- the hydrocolloid adhesive layer is generally applied to the backing layer as a hot-melt solution, which is applied in its liquid form and allowed to solidify on the backing layer. Due to the sticky and viscous properties of liquid hydrocolloid adhesives it is problematic to mix an active ingredient into the molten hydrocolloid adhesive. This is particularly relevant in industrial scale preparation of dressing products where the viscosity of the hot-melt solution may result in an uneven distribution of the active ingredient in the dressing products, even to the point where certain specimens of the dressing product contain no active ingredient.
- the present inventors have now found that the active ingredient, e.g. in the form of an extract, solution, suspension or the like, may be sprayed onto the dressing product during its manufacture.
- the invention relates to a method of preparing the dressing product of the invention.
- the method comprises the steps of: a) providing a backing layer;
- the K. africana extract may be sprayed onto the backing layer, the solidified hydrocolloid adhesive or both. It is also possible in the method of the invention to prepare a dressing product comprising several layers of the hydrocolloid adhesive where the steps b) to e) are repeated. For exam- pie, after application and formation of a layer of the hydrocolloid adhesive and application of the K. africana extract, another layer of the hydrocolloid adhesive is applied followed by spraying the K. africana extract onto the second layer of hydrocolloid extract.
- the multi-layered method allows formation of a hydrocolloid adhesive on the backing layer where the amount of K. afri- cana extract is controlled over the total thickness of the hydrocolloid adhesive layer.
- the method is generally applicable to other active ingredients.
- the invention relates to a method of preparing a dressing product for the delivery, e.g. transdermal delivery, of an active ingredient. The method comprises the steps of:
- all features of the method of preparing the dressing product of the invention i.e. the dressing product suitable for delivery of a K. africana extract, may be used in the method of preparing a dressing product for the delivery of other active ingredients, so that any embodiment described for the preparation of a dressing product with the K. africana extract is relevant also for other active ingredients, and vice versa.
- any technology for spraying a liquid onto a surface may be applied.
- the liquid with the active ingredient may be sprayed onto the surface using a spray nozzle.
- the liquid with the active ingredient is sprayed onto the backing layer and/or to the solidified hydrocolloid adhesive using ink-jet technology, e.g. piezoelectric ink-jet technology.
- Piezoelectric inkjet technology is advanta- geous in the present invention since this technology allows controlled deposition of active ingredient to the surface of interest.
- the active ingredient may be applied precisely and accurately to the dressing product.
- the dressing product contains multiple layers of the hydrocolloid adhesive it is possible to apply the active ingredient in different amounts in different layers providing control of the concentration of the active ingredient over the thickness of the dressing product.
- application of active ingredient by spraying is contact-free making the production of a dressing easier thus providing a cheaper manufacturing process. Neither of these advantages is readily obtainable when the active ingredient is mixed with a molten hydrocolloid adhesive.
- the liquid to be sprayed onto the backing layer and/or to the solidified hydrocolloid adhesive may contain any component, e.g. auxiliary components, appropriate for the spraying technology employed.
- the liquid comprises a volatile solvent, e.g. ethanol, and the methods may further comprise the step of allowing the volatile solvent to evaporate.
- the liquid comprises 30% ethanol in water, and in another embodiment the liquid comprises 70% ethanol in water; an ethanol concentration of 70% can improve evaporation of both water and ethanol due to the azeotropic effect.
- the method further comprises the step of allowing the active ingredient to diffuse into the hydrocolloid adhesive.
- the liquid is preferably generally aqueous although it may also contain a volatile solvent. Diffusion of the active ingredient into the hydrocolloid adhesive and also evaporation of the volatile solvent may be furthered by increasing the temperature over ambient temperature. Thus for example, in certain embodiments of the method of the invention the steps of allowing the volatile solvent to evaporate and/or allowing the active ingredient to diffuse into the hydrocolloid adhesive may be performed at an increased temperature, e.g. in the range of 50 to 150°C. The increased temperature will, however, generally be below the melting point of the hydrocolloid adhesive.
- the dressing product of the invention may be comprised in a carrier system.
- the carrier system may comprise a foil member supporting the dressing product and a cover member covering the surface of hydrocolloid adhesive.
- the foil member may be a sheet or layer of a material onto which the backing layer may be adhered.
- the foil member may have the same size as the backing layer, or the foil member may be larger than the backing layer so that the backing layer is surrounded by an edge or rim of the material of the foil member.
- Any appropriate material may be used for the foil member, e.g. paper or a polymer film.
- the dressing product may be adhered to the foil member using any appropriate adhesive.
- the hydrocolloid adhesive material may be applied to adhere the dressing product to the foil member.
- the superficial area of the hydrocolloid adhesive is larger than the superficial area of the backing layer so that the hydrocolloid adhesive is allowed to contact the foil member and adhere both the hydrocolloid adhesive and the backing layer, i.e. the dressing product, to the foil member.
- the carrier system further comprises a cover member.
- the cover member may be a sheet or layer of the same material as the foil member, e.g. paper or polymer film, or of another material.
- the cover member covers the hydrocolloid face of the dressing product to prevent premature contact with the hydrocolloid adhesive carrying the active ingredient.
- the cover member preferably allows easy removal of the cover member from the dressing product before application of the dressing product to the skin of a subject.
- the cover member may be siliconised, in particular on the area covering the surface of the hydrocolloid adhesive. The siliconised area allows the cover member to stick to the hydrocolloid surface while being easy to remove before application of the dressing product to the skin.
- the foil member is larger than the hydrocolloid adhesive, e.g.
- the rim of the foil area surrounding the hydrocolloid adhesive may comprise a glue for adhering the foil member to the skin of the subject.
- composition for topical application on the skin of a subject, which composition comprises:
- compositions of the invention are advantageous for the delivery of the active ingredient.
- an extract of K. Africana e.g. an ethanolic extract
- skin diseases and conditions such as psoriasis, eczemas, dermatitis and acne, are advantageously longer lasting when applied in combination with the salts and minerals from the brine.
- the cosmetic or medical composition may be a cream, gel, ointment, lotion or paste. It is also contemplated that the extract of K. africana may be replaced with any other active ingredient and that the advantages of obtaining a longer lasting effect may also be realised for other active ingredients so that the composition of the invention is suitable for transdermal delivery of any active ingredient.
- any extract of K. africana may be used in all aspects of the present invention. It is preferred that the extract is an ethanolic extract from the fruits of the plant.
- Both the dressing product and the cosmetic or medical composition of the invention provide a longer lasting effect of the active compounds of K. africana, than is obtainable when a K. africana extract is applied in a formulation without brine or directly onto the skin. Furthermore, the dressing product and the cosmetic or medical composition also provide a stronger ef- feet of the extract of K. africana.
- Brine e.g. in the form of thermal water
- the brine is a thermal water salts and minerals, e.g. other than NaCI, are advantageous to the skin.
- This effect will also be observed when the brine is derived from e.g. sea water which has been evaporated to saturation of NaCI.
- the resulting mixture produces the unique properties to the transportation of the active compounds from the surface of the skin and into the pores of the skin. Without being bound by theory it is be- lieved that the effect, e.g.
- the moisturising action, from the composition is longer lasting because of the effects of the salts of the brine as a hydrating agent.
- Appropriate thermal waters are those emerging from a depth of 800 meters from Central Europe, where the geothermal temperatures constantly is 20°C (22.1°C per km of depth or 1°F per 70 feet of depth) .
- the saturated brine generally contains about 26% sodium chloride (NaCI) and a range of different minerals.
- the cosmetic or medical composition of the invention may be formulated as a cream or as a gel.
- the composition comprises from 2 to 8 %w/w extract of K. africana, from 40 to 60 %w/w brine and from 30 to 40 %w/w excipients.
- the composition comprises from 5 to 15 %w/w extract of K. africana, from 60 to 80 %w/w brine and from 5 to 15 %w/w excipients, which comprise a gelling agent, e.g. xanthan gum.
- the excipients may be any excipients, in particular excipients known to the skilled person for formulating the composition as a cream or gel, respectively.
- the composition is a cream comprising :
- dicaprylyl carbonate 2.5 %w/w
- the gelling agent is xanthan gum.
- the dressing product and the cosmetic or medical composition of the invention are suitable for use in the treatment of skin damages, diseases and conditions, such as psoriasis, eczemas, dermatitis or acne.
- the dressing product or the composition is for use in medicine, e.g. in the treatment of skin damages, diseases and conditions.
- specific examples of the diseases and conditions are psoriasis, eczemas, dermatitis or acne.
- the dressing product or the composition is for cosmetic use.
- Figure 1 shows photographs of the skin of a subject suffering from psoriasis before and after treatment with a composition of the invention.
- the present invention relates to a dressing product comprising a backing layer and an active ingredient layer comprising an extract of Kigelia africana, which active ingredient layer is coated or adhered to the backing layer, and to a cosmetic or medical composition for topical application on the skin of a subject, which composition comprises: brine 40 - 80 %w/w
- excipients are selected from emulsifiers, suspending agents, gelling agents, binders, fillers, surfactants, anti-oxidants, preservatives, emollients, humectants, moisturisers, natural oils, UV-absorbers, sunscreens, and thickeners.
- extract should be understood broadly and the extract may be prepared using any solvent or supercritical solvent.
- the "extract” is not limited to a liquid form but also comprises the residue provided from a liquid extract after removal of the solvent.
- an extract is prepared by providing a part of a K. africana plant, e.g. fruits, leaves, bark, stem bark, root bark etc., and contacting the plant part with a solvent or supercritical solvent. Prior to extraction, the plant part may be cut into smaller pieces and/or be disrupted to increase the extraction efficiency.
- the extraction may also comprise any other processing step. For example, the plant part may be dried before extraction. In a specific embodiment the fruit of the K.
- Africana tree is cut into smaller pieces, which are dried in a ventilated oven at 75°C for approximately 48 hours before pulverising the smaller pieces.
- One part pulverised fruit is then mixed with 10 parts 30% ethanol in water solution, stirred overnight and filtered.
- the brown water/ethanol phase is spray-dried using maltodextrin as a matrix.
- the spray dried extract can be used directly in the products of the invention or it can be reconstituted in a solvent for use in the method of the invention.
- the extractant may be selected from its polarity in order to selectively extract components of the plant part; appropriate solvents and corresponding components are provided by Saini et al., 2009 and Gabriel et al., 2009 which are hereby incorporated by reference.
- an ethanolic extract of the fruits is preferred .
- the solvent is removed from the extract so that the extract is employed in a dry form.
- the extract is in a dry form.
- the extract is in a liquid form.
- the liquid form may be the extract obtained from the K. africana plant part, e.g. 30% ethanol in water, without spray drying or the liquid form may be reconstituted from a spray dried extract. It is also possible to modify an extract obtained from the K. africana plant part, e.g. when the extract is prepared using 30% ethanol in water the ethanol concentration may be increased, e.g. to 70%, prior to spraying the K.
- the content of K. africana extract is expressed in percent by weight (%w/w). This percentage is thus the dry matter content of the K. africana extract, e.g. as measured after spray drying a liquid extract, relative to the total mass of the composition.
- the extract need not be spray dried in order to estimate the dry matter content, and other methods of estimating the dry matter content are known to the skilled person.
- the dressing product of the invention and the method of preparing the dressing product require an "active ingredient".
- Any active ingredient may be used, preferably the active ingredient is an extract of K. africana.
- the extract of K. africana is not limited to bulk extract but may also be a purified single active compound from K. africana.
- the terms "active ingredient” and " C. africana extract” may be used interchangeably.
- the active ingredient may also be any other pharmaceutically or pharmacologically active agent or a natural remedy or a plant extract.
- the dressing product of the invention is or forms part of a dressing, e.g. when contained in a carrier system .
- a "dressing" is an adjunct used by a person for application to the skin, so that the dressing is in contact with the skin.
- the hydrocolloid adhesive is in contact with the skin in order to adhere to the skin for the dressing to stay in place.
- the presence of the active ingredient, e.g. compounds from K. afri- cana, in the hydrocolloid adhesive provides that the active ingredient is delivered to the skin.
- the dressing may be suitable for application on any part of the subject's skin.
- the dressing product may be used in the treatment of skin damages, diseases and conditions, e.g. psoriasis, eczemas, dermatitis or acne.
- the dressing product is prepared by applying a molten hot-melt hydrocolloid to the backing layer.
- a molten hot-melt hydrocolloid Any hydrocolloid that may be applied in a molten form is considered a "hot-melt hydrocolloid" in the context of the invention.
- Exemplary hot-melt hydrocolloids are carboxymethyl-cellulose or other cellulose derivatives, agar, carrageenan, gelatin, pectin, xanthan gum, gum arabic, guar gum, locust bean gum, and alginate.
- the hydrocoiioid adhesive may also be any mixture of these components, and the hydrocoiioid may also comprise other components, e.g. polymers, excipients or the like.
- the hydrocoiioid adhesive comprises carboxymethyl-cellulose, polyisobutylene, pectin and option- ally one or more further components.
- the hydrocoiioid adhesive may contain about 40% by weight of low molecular weight polyisobutylene, about 20% by weight of sodium carboxymethylcellulose, about 20% by weight of pectin, and about 20% by weight of gelatin.
- the hydrocoiioid may generally serve two functions in the dressing product, and both rely on the ability of the hydrocoiioid material to absorb aqueous liquids. This ability allows the hydrocoiioid material to absorb an active ingredient and deliver it to the skin of a subject.
- liquids such as wound exudates
- liquids may be absorbed to make the hydrocoiioid material swell, forming a gel which is held within the structure of the hydrocoiioid matrix.
- the extract of K. Africana is kept in place by the hydrocoiioid matrix and is therefore in prolonged contact with the skin (as opposed to when used in a topical ointment).
- This provides an enhancement of the properties of K. Africana due to the prolonged active exposure of the extract to the skin. No dressing products of the prior art provide this effect.
- the hydrocoiioid adhesive may be applied to a large surface of the backing material, e.g. a polyurethane film, in particular a permeable polyure- thane film, before being allowed to solidify.
- the thickness of the layer of the hydrocoiioid adhesive may be from about 100 ⁇ to about 5 mm, e.g. about 1 mm.
- the extract of K. afri- cana or the solution of the active ingredient is sprayed onto the hydrocoiioid adhesive, e.g. the surface of the hydrocoiioid adhesive, for example using piezoelectric ink-jet technology.
- the "piezoelectric ink-jet technology” allows precise deposition of droplets of even picoliter volumes of the extract of K. africana or the solution of the active ingredient.
- the liquid may be spotted in volumes from about 1 pL to about 1 ⁇ _ or more, e.g. about 10 pL, about 100 pL, about 1 nl_, about 10 nl_ or about 100 nl_. This may create spot diameters of extract or solution of about 1 ⁇ to about 1 mm.
- This control of application of active compounds by mixing the active compound in a molten hot-melt hydrocoiioid adhesive is not possible.
- Exemplary ink-jet deposition equipment comprises Dimatix Materials Printers, e.g.
- the extract may be adjusted to be suitable for the specific ink-jet equipment.
- the viscosity of the extract may be raised or lowered, e.g. by addition of glycol or ethanol, respectively, to the extract, to bring the viscosity within the range of from about 1 to 50 mPas, e.g. about 10 mPas.
- the viscosity may also be outside these ranges.
- the extract may also be filtered, e.g. through a 0.45 ⁇ or 0.2 ⁇ filter, prior to loading in the ink-jet equipment.
- the extract may now be allowed to diffuse into the hydrocol- loid adhesive, or a volatile solvent may be allowed to evaporate from the hydrocolloid adhesive.
- the extract may for example be prepared as outlined above.
- the spray dried extract is dissolved or suspended in a liquid appropriate for the piezoelectric ink-jet technology.
- the liquid may comprise ethanol as a solvent, with the extract being present in an amount of from 0.1 %w/w to 20 %w/w or more, e.g. from 1 %w/w to 10 %w/w, expressed as the dry weight content of the extract, e.g. the weight of the spray dried extract to the total weight of the solution.
- the extract is not spray dried but may be the filtered extract prepared as outlined above, optionally modified to bring the dry mat- ter content and/or the solvent composition within the desired ranges, e.g. by addition of liquid, such as ethanol, or the removal of liquid.
- liquid such as ethanol
- each piece of dressing product may be applied to a larger sheet of paper, so that the piece of dressing product can be adhered to the piece of paper, e.g. by applying the same hydrocolloid material as used in the preparation of the dressing product in a molten state around the perimeter of the piece of the dressing product.
- the piece of paper now provides the foil member for the piece of dressing product.
- the surface of the hydrocolloid adhesive may now be covered with a cover member, e.g. of the same size and shape as the foil member.
- the cover member is preferably siliconised on the surface contacting the hydrocolloid adhesive in order to allow easy removal and application of the dressing product to the skin of a subject.
- the carrier system comprising the dressing product can then be packaged as desired.
- the invention in another aspect relates to a cosmetic or medical composition
- a cosmetic or medical composition comprising the extract of K. africana and a brine, in particular a brine derived from a thermal water.
- the term "brine” refers to a saturated aqueous salt solution.
- the salt is preferably mineral salt or sea salt, and the major cationic component of the brine is thus sodium ions, and the major anionic component is chloride ions.
- Other ionic components may be sulphate, magnesium, calcium, potassium, bicarbonate, bromide, borate, and strontium.
- the brine is provided by concentrating seawater or saline groundwater.
- seawater or saline groundwater may be heated to evaporate water and to precipitate salts; separation of the precipitated salts will provide the brine.
- the relative contents of sodium and chloride in solution are low- ered compared to the starting material, e.g. sea water, so that the brine will be enriched in other ions, while being saturated in the major components, e.g. sodium and chloride ions.
- the brine is a "thermal water" derived from geothermal heated groundwater, in particular from groundwater with a high mineral and/or salts content.
- the brine e.g. as a saturated solution, comprises about 26% NaCI.
- an "excipient” is any generally pharmacologically inactive substance used as an aid in the formulation of the cosmetic or medical composition, or which provides another non- pharmacologically related function to the composition. Any excipient provid- ing a desired functionality may be employed in the composition of the invention.
- the cosmetic or medical composition may comprise one or more excipi- ents selected from emulsifiers, suspending agents, gelling agents, binders, fillers, surfactants, anti-oxidants, preservatives, emollients, humectants, moisturisers, natural oils, UV-absorbers, sunscreens, and thickeners. Excipi- ents are well-known to the skilled person, e.g. from the European Pharmacopoeia.
- the cosmetic or medical composition is preferably formulated as a cream or a gel.
- a "cream” is a topical preparation for application to the skin generally consisting of an emulsion of an oil phase and a water phase with an appropriate emulsifier. When the composition is formulated as a cream it can be considered to be an oil-in-water emulsion.
- a “gel” is an aqueous composition comprising a gelling agent, which may be a hydrophilic polymer, allowing formation of a viscous solution or suspension. Thus, a cream can be described as "greasy” and the gel can be described as "dry”.
- a greasy cream is especially advantageous when applied to the skin of a subject suffering from dermatitis or psoriasis since the cream will strengthen and restore the lipids in the epidermis which will strengthen the barrier characteristics of the skin.
- a dry gel is especially advantageous when applied to the skin of a subject suffering from acne since the gel will form a thin layer on the skin and pro- vide the effects of the brine and the extract of K. africana. The advantages of the dry gel are also relevant for a subject suffering from psoriasis.
- the composition of the invention may be applied to any part of the skin of a subject, e.g. to skin near or at the subject's joints.
- composition of the invention in the form of a gel was prepared.
- the gel comprised :
- the gel was tested on a subject suffering from psoriasis.
- a typical way of treatment of psoriasis damaged skin : 2-3 times of daily application of the gel containing K. africana and brine.
- the gel provides a thin protecting layer with a significant improving result discovered through a number of tests on psoriasis patients.
- the brine is known to give the protecting layer effect on skin, and in combination with the described positive effects from K. africana achieves a better treatment than could be obtained with either brine or K. africana alone, where the active compounds obtain a longer and more effective contact to skin.
- the pictures in Figure 1 show the results before and after 3 weeks of treatment (3 x applications per day in 21 days) of a psoriasis damaged skin on a left foot.
- the picture in Figure la shows the untreated skin
- the picture in Figure lb shows the result after 21 days of treatment.
- the patient concluded that the level of irritation and itching was significantly bettered using the gel containing K. africana and brine compared to his experience with products only containing brine. This patient describes positive effects after the first 3 times of application. This example is representative for all the conducted tests in this group of patients.
- composition of the invention in the form of a cream was prepared The cream comprised :
- dicaprylyl carbonate 2.5 %w/w
- a typical way of using the cream containing K. africana and brine The product was applied on the irritated skin 2-3 times per day or as needed. Compared to products only containing brine the test on patients conclude, that the combination of K. africana and brine gives a significant healing effect. The itching stops after 1-2 applications and this effect continued as long as the product was applied.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a dressing product comprising a backing layer and an active ingredient layer comprising an extract of Kigelia africana, which active ingredient layer is coated or adhered to the backing layer and to a method of producing the dressing product. The invention further relates to a cosmetic or medical composition for topical application on the skin of a subject, which composition comprises: brine 40 - 80 %w/w an extract of Kigelia africana 2 - 15 %w/w one or more excipients 5 - 50 %w/w water balance which excipients are selected from emulsifiers, suspending agents, gelling agents, binders, fillers, surfactants, anti-oxidants, preservatives, emollients, humectants, moisturisers, natural oils, UV-absorbers, sunscreens, and thickeners. The dressing product and the composition are suitable for use in the treatment of skin damages, diseases and conditions.
Description
A dressing product and a cosmetic or medical composition with Kigelia africana
Field of the invention
The present invention relates to a dressing product comprising an ex- tract of Kigelia africana, and to a method of producing the dressing product. The invention also relates to a cosmetic or medical composition for topical application on the skin of a subject, which composition comprises an extract of K. africana. The dressing product and the composition are suitable for use in the treatment of skin damages, diseases and conditions. The dressing product and the composition provide a longer lasting effect of the activities of K. africana.
Background
In general the use of extracts and other products from the plant Kige- lia africana for the treatment of skin diseases and conditions is well known. For example, WO 2006/002443 describes pharmaceutical and cosmetic preparations based on K. africana. The preparations of WO 2006/002443 may be in the form of a cream, ointment or gel, and it is intended as a general pain reliever, an anti-septic, an anti-inflammatory or an anti-pruritic. Specific applications are for the treatment of cuts, bruises, insect bites, stings, sun exposure of the skin, psoriasis, eczema, solar keratosis, and cancerous sores.
FR 2 759 910 also describes cosmetic compositions for skin care and body care containing extracts of K. africana. The may be used for firming of the bust, limiting hair loss, and limiting hair growth. Further skin creams of K. africana are provided by ZW 10292.
The constituents of K. africana, their extraction and known medical effects are described in Kigelia africana (Lam.) Benth - An overview, S. Saini, H. Kaur, B. Vherma, Ripudaman, S. K. Singh, 2009, Nature Product Radiance, 8: 190-197, and Comprehensive scientific demystification of Kigelia africana : A review, Olatunji A. Gabriel and Atolani Olubunmi, 2009, African Journal of Pure and Applied Chemistry, 3: 158-164. Saini et al., 2009, describe how an ethanol extract was tested for pharmacological activity in animal studies in mice and in cell lines. It was concluded from the tests that ethanolic extracts
of K. Africana have a significant positive effect on use against skin irritation / oedema and a significant antibacterial/ antimicrobial inhibitory effect on both Gram-positive and Gram-negative bacteria
There is however still a need for further and improved products relying on the medical and cosmetic activities of K. africana. In particular, there is a need for products providing a longer lasting effect of the activities of K. africana. It is the aim of the present invention to provide improved medical and cosmetic compositions and dressings for delivery of K. africana extracts and methods for their production.
Summary of the invention
A first aspect the present invention relates to a dressing product comprising a backing layer and an active ingredient layer comprising an extract of Kigelia africana, which active ingredient layer is coated or adhered to the backing layer. The extract, e.g. an ethanolic extract, from K. Africana, e.g. the fruit, shows a significant effect on treatment skin diseases and conditions, such as psoriasis, eczemas, dermatitis and acne. The dressing product of the invention is suitable for application to the skin of a subject, e.g. a human subject, in order to provide the effect of the K. africana extract to the skin of the subject. The active ingredient layer may comprise an adhesive, preferably a hydrocolloid adhesive, allowing the dressing product to adhere to the skin of the subject. Hydrocolloid adhesives provide excellent adhesive properties to the skin of subject, so that the dressing sticks efficiently. Furthermore, the hydrocolloid adhesive will serve as a carrier for the K. africana extract and allowing the active compounds of K. africana to diffuse to the skin of the subject. In particular, the hydrocolloid adhesive absorbs moisture from damaged skin forming a liquid gel over the damaged skin resulting in delivery of the K. africana extract to the damaged skin. The active ingredient layer, especially in the form of a hydrocolloid adhesive, provides that the K. africana extract is kept in place on the skin. Thus, the combined effects of the stickiness of the hydrocolloid adhesive, and the aqueous nature, i.e. the "gel effect", allow a long-term diffusion of the active compounds of K. africana to the skin of the subject where the dressing product is applied. Such a long-term effect cannot readily be obtained when the K. africana extract is applied directly to the skin
or via a dressing not comprising a hydrocolloid adhesive. Any hydrocolloid adhesive may be employed for the dressing of the invention.
The backing layer may be any suitable material, such as a polymer film or film of non-woven polymer fibres. The polymer film may be permeable to gasses, e.g. to allow diffusion of water molecules from the skin or the dressing product, or to allow diffusion of oxygen from the surroundings to the skin. The polymer film may also be non-permeable. A preferred polymer material is polyurethane.
The active ingredient layer is coated on or adhered to the backing layer to form the dressing product. The hydrocolloid adhesive layer is generally applied to the backing layer as a hot-melt solution, which is applied in its liquid form and allowed to solidify on the backing layer. Due to the sticky and viscous properties of liquid hydrocolloid adhesives it is problematic to mix an active ingredient into the molten hydrocolloid adhesive. This is particularly relevant in industrial scale preparation of dressing products where the viscosity of the hot-melt solution may result in an uneven distribution of the active ingredient in the dressing products, even to the point where certain specimens of the dressing product contain no active ingredient. The present inventors have now found that the active ingredient, e.g. in the form of an extract, solution, suspension or the like, may be sprayed onto the dressing product during its manufacture.
Thus, in another aspect the invention relates to a method of preparing the dressing product of the invention. The method comprises the steps of: a) providing a backing layer;
b) applying a hot-melt hydrocolloid adhesive in a liquid form to the backing layer;
c) allowing the liquid hydrocolloid adhesive to solidify;
d) providing a Kigelia africana extract; and
e) spraying the K. africana extract onto the backing layer and/or to the solidified hydrocolloid adhesive.
Thus, the K. africana extract may be sprayed onto the backing layer, the solidified hydrocolloid adhesive or both. It is also possible in the method of the invention to prepare a dressing product comprising several layers of the hydrocolloid adhesive where the steps b) to e) are repeated. For exam- pie, after application and formation of a layer of the hydrocolloid adhesive
and application of the K. africana extract, another layer of the hydrocolloid adhesive is applied followed by spraying the K. africana extract onto the second layer of hydrocolloid extract. The multi-layered method allows formation of a hydrocolloid adhesive on the backing layer where the amount of K. afri- cana extract is controlled over the total thickness of the hydrocolloid adhesive layer.
It is also contemplated that the method is generally applicable to other active ingredients. Thus, in another aspect the invention relates to a method of preparing a dressing product for the delivery, e.g. transdermal delivery, of an active ingredient. The method comprises the steps of:
a) providing a backing layer;
b) applying a hot-melt hydrocolloid adhesive in a liquid form to the backing layer;
c) allowing the liquid hydrocolloid adhesive to solidify;
d) providing a solution or suspension of an active ingredient; and e) spraying the solution or suspension of the active ingredient onto the backing layer and/or to the solidified hydrocolloid adhesive.
In general all features of the method of preparing the dressing product of the invention, i.e. the dressing product suitable for delivery of a K. africana extract, may be used in the method of preparing a dressing product for the delivery of other active ingredients, so that any embodiment described for the preparation of a dressing product with the K. africana extract is relevant also for other active ingredients, and vice versa.
In the methods of the invention any technology for spraying a liquid onto a surface may be applied. For example, the liquid with the active ingredient may be sprayed onto the surface using a spray nozzle. It is preferred that the liquid with the active ingredient is sprayed onto the backing layer and/or to the solidified hydrocolloid adhesive using ink-jet technology, e.g. piezoelectric ink-jet technology. Piezoelectric inkjet technology is advanta- geous in the present invention since this technology allows controlled deposition of active ingredient to the surface of interest. Thus, the active ingredient may be applied precisely and accurately to the dressing product. Furthermore, it is possible to control the location of application of the active ingred ient on the dressing product allowing production of a dressing product con- taining multiple, e.g. different, active ingredients distributed in discrete and
separate areas on the dressing product. When the dressing product contains multiple layers of the hydrocolloid adhesive it is possible to apply the active ingredient in different amounts in different layers providing control of the concentration of the active ingredient over the thickness of the dressing product. Moreover application of active ingredient by spraying is contact-free making the production of a dressing easier thus providing a cheaper manufacturing process. Neither of these advantages is readily obtainable when the active ingredient is mixed with a molten hydrocolloid adhesive.
The liquid to be sprayed onto the backing layer and/or to the solidified hydrocolloid adhesive, e.g. the solution or suspension of the active ingredient or the K. africana extract, may contain any component, e.g. auxiliary components, appropriate for the spraying technology employed. In an embodiment of the invention the liquid comprises a volatile solvent, e.g. ethanol, and the methods may further comprise the step of allowing the volatile solvent to evaporate. In a specific embodiment the liquid comprises 30% ethanol in water, and in another embodiment the liquid comprises 70% ethanol in water; an ethanol concentration of 70% can improve evaporation of both water and ethanol due to the azeotropic effect. In another embodiment the method further comprises the step of allowing the active ingredient to diffuse into the hydrocolloid adhesive. In this embodiment the liquid is preferably generally aqueous although it may also contain a volatile solvent. Diffusion of the active ingredient into the hydrocolloid adhesive and also evaporation of the volatile solvent may be furthered by increasing the temperature over ambient temperature. Thus for example, in certain embodiments of the method of the invention the steps of allowing the volatile solvent to evaporate and/or allowing the active ingredient to diffuse into the hydrocolloid adhesive may be performed at an increased temperature, e.g. in the range of 50 to 150°C. The increased temperature will, however, generally be below the melting point of the hydrocolloid adhesive.
The dressing product of the invention, e.g. the dressing product obtainable in the method of the invention, may be comprised in a carrier system. The carrier system may comprise a foil member supporting the dressing product and a cover member covering the surface of hydrocolloid adhesive.
The foil member may be a sheet or layer of a material onto which the backing layer may be adhered. The foil member may have the same size as
the backing layer, or the foil member may be larger than the backing layer so that the backing layer is surrounded by an edge or rim of the material of the foil member. Any appropriate material may be used for the foil member, e.g. paper or a polymer film. The dressing product may be adhered to the foil member using any appropriate adhesive. For example, the hydrocolloid adhesive material may be applied to adhere the dressing product to the foil member. In a specific embodiment, the superficial area of the hydrocolloid adhesive is larger than the superficial area of the backing layer so that the hydrocolloid adhesive is allowed to contact the foil member and adhere both the hydrocolloid adhesive and the backing layer, i.e. the dressing product, to the foil member.
The carrier system further comprises a cover member. The cover member may be a sheet or layer of the same material as the foil member, e.g. paper or polymer film, or of another material. The cover member covers the hydrocolloid face of the dressing product to prevent premature contact with the hydrocolloid adhesive carrying the active ingredient. The cover member preferably allows easy removal of the cover member from the dressing product before application of the dressing product to the skin of a subject. For example, the cover member may be siliconised, in particular on the area covering the surface of the hydrocolloid adhesive. The siliconised area allows the cover member to stick to the hydrocolloid surface while being easy to remove before application of the dressing product to the skin. When the foil member is larger than the hydrocolloid adhesive, e.g. has a larger superficial area, it is possible to prevent that the hydrocolloid surface is touched directly by the fingers of the applicant. Thus, the applicant can remove the cover member without touching the hydrocolloid adhesive surface and apply the dressing product to the skin. Further, when the foil member is larger than the hydrocolloid adhesive, e.g. has a larger superficial area the rim of the foil area surrounding the hydrocolloid adhesive may comprise a glue for adhering the foil member to the skin of the subject.
In another aspect the invention relates to a cosmetic or medical composition for topical application on the skin of a subject, which composition comprises:
brine 40 - 80 %w/w
an extract of Kigelia africana 2 - 15 %w/w
one or more excipients 5 - 50 %w/w
water balance
which excipients are selected from emulsifiers, suspending agents, gelling agents, binders, fillers, surfactants, anti-oxidants, preservatives, emol- lients, humectants, moisturisers, natural oils, UV-absorbers, sunscreens, and thickeners. The present inventors have now surprisingly found that the composition of the invention is advantageous for the delivery of the active ingredient. Thus, the effects of an extract of K. Africana, e.g. an ethanolic extract, on skin diseases and conditions, such as psoriasis, eczemas, dermatitis and acne, are advantageously longer lasting when applied in combination with the salts and minerals from the brine. By applying the composition, e.g. as a gel or cream, to the skin of a subject suffering from psoriasis, the psoriasis significantly turns into more relaxed skin after 2-3 applications in 3 days, and after 5-6 days of treatment the skin stops itching. Moreover, it has surpris- ingly been found that the extract of K. Africana and the brine act synergisti- cally so that the effect can be said to be stronger than when either of the brine or the extract of K. Africana are applied individually. The cosmetic or medical composition may be a cream, gel, ointment, lotion or paste. It is also contemplated that the extract of K. africana may be replaced with any other active ingredient and that the advantages of obtaining a longer lasting effect may also be realised for other active ingredients so that the composition of the invention is suitable for transdermal delivery of any active ingredient.
Any extract of K. africana may be used in all aspects of the present invention. It is preferred that the extract is an ethanolic extract from the fruits of the plant. Both the dressing product and the cosmetic or medical composition of the invention provide a longer lasting effect of the active compounds of K. africana, than is obtainable when a K. africana extract is applied in a formulation without brine or directly onto the skin. Furthermore, the dressing product and the cosmetic or medical composition also provide a stronger ef- feet of the extract of K. africana.
Brine, e.g. in the form of thermal water, is known from its positive effects to damaged skin, and to drive other active ingredients into the skin's layers and pores. In particular, when the brine is a thermal water salts and minerals, e.g. other than NaCI, are advantageous to the skin. This effect will also be observed when the brine is derived from e.g. sea water which has
been evaporated to saturation of NaCI. In combination with the known positive effects from K. africana the resulting mixture produces the unique properties to the transportation of the active compounds from the surface of the skin and into the pores of the skin. Without being bound by theory it is be- lieved that the effect, e.g. the moisturising action, from the composition is longer lasting because of the effects of the salts of the brine as a hydrating agent. Appropriate thermal waters are those emerging from a depth of 800 meters from Central Europe, where the geothermal temperatures constantly is 20°C (22.1°C per km of depth or 1°F per 70 feet of depth) . The saturated brine generally contains about 26% sodium chloride (NaCI) and a range of different minerals.
The cosmetic or medical composition of the invention may be formulated as a cream or as a gel. When formulated as a cream the composition comprises from 2 to 8 %w/w extract of K. africana, from 40 to 60 %w/w brine and from 30 to 40 %w/w excipients. When formulated as a gel the composition comprises from 5 to 15 %w/w extract of K. africana, from 60 to 80 %w/w brine and from 5 to 15 %w/w excipients, which comprise a gelling agent, e.g. xanthan gum. The excipients may be any excipients, in particular excipients known to the skilled person for formulating the composition as a cream or gel, respectively. In a specific embodiment the composition is a cream comprising :
brine 50 %w/w
an extract of K. africana 5 %w/w
octyldodecyl stearate 10 %w/w
cetyl alcohol 8 %w/w
glycerine 4.2 %w/w
dicaprylyl carbonate 2.5 %w/w
lauryl polyglucose 2 %w/w
cera alba 2 %w/w
PEG-50 Shea butter 1.25 %w/w
glycerol stearate 1 %w/w
PEG-75 Stearate 1 %w/w
ceteth-20 1 %w/w
steareth-20 1 %w/w
polyg lyce ry 1- 2 d i polyhyd roxystea rate 0.5 %w/w
tocopherol 0.15 %w/w
allantoin 0.13 %w/w
water balance.
In a specific embodiment the composition is a gel comprising :
brine 70 %w/w
an extract of K. africana 10 %w/w
glycerin 5 %w/w
propylene glycol 2 %w/w
xanthan gum 1 %w/w
water balance, where the gelling agent is xanthan gum.
The dressing product and the cosmetic or medical composition of the invention are suitable for use in the treatment of skin damages, diseases and conditions, such as psoriasis, eczemas, dermatitis or acne. Thus, in an embodiment of the invention the dressing product or the composition is for use in medicine, e.g. in the treatment of skin damages, diseases and conditions. Specific examples of the diseases and conditions are psoriasis, eczemas, dermatitis or acne. In another embodiment of the invention the dressing product or the composition is for cosmetic use.
Brief description of the figures
The invention will be readily understood from the following detailed description in conjunction with the accompanying figure, in which
Figure 1 shows photographs of the skin of a subject suffering from psoriasis before and after treatment with a composition of the invention.
Detailed description of the invention
In order to more fully explain the invention it is disclosed in more detail below, and definitions of the terms used throughout the document are given. The present invention relates to a dressing product comprising a backing layer and an active ingredient layer comprising an extract of Kigelia africana, which active ingredient layer is coated or adhered to the backing layer, and to a cosmetic or medical composition for topical application on the skin of a subject, which composition comprises:
brine 40 - 80 %w/w
an extract of Kigelia africana 2 - 15 %w/w
one or more excipients 5 - 50 %w/w
water balance
which excipients are selected from emulsifiers, suspending agents, gelling agents, binders, fillers, surfactants, anti-oxidants, preservatives, emollients, humectants, moisturisers, natural oils, UV-absorbers, sunscreens, and thickeners.
The term "extract" should be understood broadly and the extract may be prepared using any solvent or supercritical solvent. The "extract" is not limited to a liquid form but also comprises the residue provided from a liquid extract after removal of the solvent. In general, an extract is prepared by providing a part of a K. africana plant, e.g. fruits, leaves, bark, stem bark, root bark etc., and contacting the plant part with a solvent or supercritical solvent. Prior to extraction, the plant part may be cut into smaller pieces and/or be disrupted to increase the extraction efficiency. The extraction may also comprise any other processing step. For example, the plant part may be dried before extraction. In a specific embodiment the fruit of the K. Africana tree is cut into smaller pieces, which are dried in a ventilated oven at 75°C for approximately 48 hours before pulverising the smaller pieces. One part pulverised fruit is then mixed with 10 parts 30% ethanol in water solution, stirred overnight and filtered. The brown water/ethanol phase is spray-dried using maltodextrin as a matrix. The spray dried extract can be used directly in the products of the invention or it can be reconstituted in a solvent for use in the method of the invention. In general, the extractant may be selected from its polarity in order to selectively extract components of the plant part; appropriate solvents and corresponding components are provided by Saini et al., 2009 and Gabriel et al., 2009 which are hereby incorporated by reference. An ethanolic extract of the fruits is preferred . In certain embodiments, the solvent is removed from the extract so that the extract is employed in a dry form. For the cosmetic or medical product of the invention it is preferred that the extract is in a dry form. In the method of the invention the extract is in a liquid form. The liquid form may be the extract obtained from the K. africana plant part, e.g. 30% ethanol in water, without spray drying or the liquid form may be reconstituted from a spray dried extract. It is also possible to
modify an extract obtained from the K. africana plant part, e.g. when the extract is prepared using 30% ethanol in water the ethanol concentration may be increased, e.g. to 70%, prior to spraying the K. africana extract onto the backing layer and/or to the solidified hydrocolloid adhesive. In general, the content of K. africana extract is expressed in percent by weight (%w/w). This percentage is thus the dry matter content of the K. africana extract, e.g. as measured after spray drying a liquid extract, relative to the total mass of the composition. The extract need not be spray dried in order to estimate the dry matter content, and other methods of estimating the dry matter content are known to the skilled person.
The dressing product of the invention and the method of preparing the dressing product require an "active ingredient". Any active ingredient may be used, preferably the active ingredient is an extract of K. africana. The extract of K. africana is not limited to bulk extract but may also be a purified single active compound from K. africana. The terms "active ingredient" and " C. africana extract" may be used interchangeably. The active ingredient may also be any other pharmaceutically or pharmacologically active agent or a natural remedy or a plant extract.
The dressing product of the invention is or forms part of a dressing, e.g. when contained in a carrier system . In terms of the invention a "dressing" is an adjunct used by a person for application to the skin, so that the dressing is in contact with the skin. In particular, the hydrocolloid adhesive is in contact with the skin in order to adhere to the skin for the dressing to stay in place. The presence of the active ingredient, e.g. compounds from K. afri- cana, in the hydrocolloid adhesive provides that the active ingredient is delivered to the skin. The dressing may be suitable for application on any part of the subject's skin. The dressing product may be used in the treatment of skin damages, diseases and conditions, e.g. psoriasis, eczemas, dermatitis or acne.
In an embodiment of the invention, the dressing product is prepared by applying a molten hot-melt hydrocolloid to the backing layer. Any hydrocolloid that may be applied in a molten form is considered a "hot-melt hydrocolloid" in the context of the invention. Exemplary hot-melt hydrocolloids are carboxymethyl-cellulose or other cellulose derivatives, agar, carrageenan, gelatin, pectin, xanthan gum, gum arabic, guar gum, locust bean gum, and
alginate. The hydrocoiioid adhesive may also be any mixture of these components, and the hydrocoiioid may also comprise other components, e.g. polymers, excipients or the like. In a specific embodiment the hydrocoiioid adhesive comprises carboxymethyl-cellulose, polyisobutylene, pectin and option- ally one or more further components. For example, the hydrocoiioid adhesive may contain about 40% by weight of low molecular weight polyisobutylene, about 20% by weight of sodium carboxymethylcellulose, about 20% by weight of pectin, and about 20% by weight of gelatin. The hydrocoiioid may generally serve two functions in the dressing product, and both rely on the ability of the hydrocoiioid material to absorb aqueous liquids. This ability allows the hydrocoiioid material to absorb an active ingredient and deliver it to the skin of a subject. Furthermore, liquids, such as wound exudates, may be absorbed to make the hydrocoiioid material swell, forming a gel which is held within the structure of the hydrocoiioid matrix. As this process happens the extract of K. Africana is kept in place by the hydrocoiioid matrix and is therefore in prolonged contact with the skin (as opposed to when used in a topical ointment). This in turn provides an enhancement of the properties of K. Africana due to the prolonged active exposure of the extract to the skin. No dressing products of the prior art provide this effect.
The hydrocoiioid adhesive may be applied to a large surface of the backing material, e.g. a polyurethane film, in particular a permeable polyure- thane film, before being allowed to solidify. The thickness of the layer of the hydrocoiioid adhesive may be from about 100 μηι to about 5 mm, e.g. about 1 mm. After solidification of the hydrocoiioid adhesive, the extract of K. afri- cana or the solution of the active ingredient is sprayed onto the hydrocoiioid adhesive, e.g. the surface of the hydrocoiioid adhesive, for example using piezoelectric ink-jet technology. The "piezoelectric ink-jet technology" allows precise deposition of droplets of even picoliter volumes of the extract of K. africana or the solution of the active ingredient. Thus for example, the liquid may be spotted in volumes from about 1 pL to about 1 μΙ_ or more, e.g. about 10 pL, about 100 pL, about 1 nl_, about 10 nl_ or about 100 nl_. This may create spot diameters of extract or solution of about 1 μηι to about 1 mm. This control of application of active compounds by mixing the active compound in a molten hot-melt hydrocoiioid adhesive is not possible. Exemplary ink-jet deposition equipment comprises Dimatix Materials Printers, e.g. DMP-2800,
DMP-3000, DMP-5000, DMP-5005, supplied by Fujifilm Dimatix, although the invention is not limited to these printers. In general, the extract may be adjusted to be suitable for the specific ink-jet equipment. For example, the viscosity of the extract may be raised or lowered, e.g. by addition of glycol or ethanol, respectively, to the extract, to bring the viscosity within the range of from about 1 to 50 mPas, e.g. about 10 mPas. The viscosity may also be outside these ranges. The extract may also be filtered, e.g. through a 0.45 μηι or 0.2 μηι filter, prior to loading in the ink-jet equipment. Following application by spraying, the extract may now be allowed to diffuse into the hydrocol- loid adhesive, or a volatile solvent may be allowed to evaporate from the hydrocolloid adhesive. The extract may for example be prepared as outlined above. In a specific embodiment the spray dried extract is dissolved or suspended in a liquid appropriate for the piezoelectric ink-jet technology. For example, the liquid may comprise ethanol as a solvent, with the extract being present in an amount of from 0.1 %w/w to 20 %w/w or more, e.g. from 1 %w/w to 10 %w/w, expressed as the dry weight content of the extract, e.g. the weight of the spray dried extract to the total weight of the solution. In another embodiment the extract is not spray dried but may be the filtered extract prepared as outlined above, optionally modified to bring the dry mat- ter content and/or the solvent composition within the desired ranges, e.g. by addition of liquid, such as ethanol, or the removal of liquid.
Following application of the K. africana extract or another active ingredient to the hydrocolloid adhesive, smaller pieces may be punched out of the dressing product, e.g. in sizes of 2 by 2 cm or larger or smaller as desired. The smaller pieces of the dressing product may then be applied to a foil member, e.g. a sheet of paper. For example, each piece of dressing product may be applied to a larger sheet of paper, so that the piece of dressing product can be adhered to the piece of paper, e.g. by applying the same hydrocolloid material as used in the preparation of the dressing product in a molten state around the perimeter of the piece of the dressing product. The piece of paper now provides the foil member for the piece of dressing product. The surface of the hydrocolloid adhesive may now be covered with a cover member, e.g. of the same size and shape as the foil member. The cover member is preferably siliconised on the surface contacting the hydrocolloid adhesive in order to allow easy removal and application of the dressing product to the
skin of a subject. The carrier system comprising the dressing product can then be packaged as desired.
In another aspect the invention relates to a cosmetic or medical composition comprising the extract of K. africana and a brine, in particular a brine derived from a thermal water. In the context of the present invention the term "brine" refers to a saturated aqueous salt solution. The salt is preferably mineral salt or sea salt, and the major cationic component of the brine is thus sodium ions, and the major anionic component is chloride ions. Other ionic components may be sulphate, magnesium, calcium, potassium, bicarbonate, bromide, borate, and strontium. In certain embodiments the brine is provided by concentrating seawater or saline groundwater. For example seawater or saline groundwater may be heated to evaporate water and to precipitate salts; separation of the precipitated salts will provide the brine. In a specific embodiment the relative contents of sodium and chloride in solution are low- ered compared to the starting material, e.g. sea water, so that the brine will be enriched in other ions, while being saturated in the major components, e.g. sodium and chloride ions. In another embodiment, the brine is a "thermal water" derived from geothermal heated groundwater, in particular from groundwater with a high mineral and/or salts content. In general, the brine, e.g. as a saturated solution, comprises about 26% NaCI.
In the context of the invention an "excipient" is any generally pharmacologically inactive substance used as an aid in the formulation of the cosmetic or medical composition, or which provides another non- pharmacologically related function to the composition. Any excipient provid- ing a desired functionality may be employed in the composition of the invention. The cosmetic or medical composition may comprise one or more excipi- ents selected from emulsifiers, suspending agents, gelling agents, binders, fillers, surfactants, anti-oxidants, preservatives, emollients, humectants, moisturisers, natural oils, UV-absorbers, sunscreens, and thickeners. Excipi- ents are well-known to the skilled person, e.g. from the European Pharmacopoeia.
The cosmetic or medical composition is preferably formulated as a cream or a gel. A "cream" is a topical preparation for application to the skin generally consisting of an emulsion of an oil phase and a water phase with an appropriate emulsifier. When the composition is formulated as a cream it can
be considered to be an oil-in-water emulsion. A "gel" is an aqueous composition comprising a gelling agent, which may be a hydrophilic polymer, allowing formation of a viscous solution or suspension. Thus, a cream can be described as "greasy" and the gel can be described as "dry". A greasy cream is especially advantageous when applied to the skin of a subject suffering from dermatitis or psoriasis since the cream will strengthen and restore the lipids in the epidermis which will strengthen the barrier characteristics of the skin. A dry gel is especially advantageous when applied to the skin of a subject suffering from acne since the gel will form a thin layer on the skin and pro- vide the effects of the brine and the extract of K. africana. The advantages of the dry gel are also relevant for a subject suffering from psoriasis. The composition of the invention may be applied to any part of the skin of a subject, e.g. to skin near or at the subject's joints.
The invention is now described in the following non-limiting examples.
Examples
Example 1
A composition of the invention in the form of a gel was prepared. The gel comprised :
brine 70 %w/w
an extract of K. africana 10 %w/w
glycerin 5 %w/w
propylene glycol 2 %w/w
xanthan gum 1 %w/w
water balance.
The gel was tested on a subject suffering from psoriasis. A typical way of treatment of psoriasis damaged skin : 2-3 times of daily application of the gel containing K. africana and brine. The gel provides a thin protecting layer with a significant improving result discovered through a number of tests on psoriasis patients. The brine is known to give the protecting layer effect on skin, and in combination with the described positive effects from K. africana achieves a better treatment than could be obtained with either brine or K. africana alone, where the active compounds obtain a longer and more effective contact to skin. The pictures in Figure 1 show the results before and after
3 weeks of treatment (3 x applications per day in 21 days) of a psoriasis damaged skin on a left foot. The picture in Figure la shows the untreated skin, and the picture in Figure lb shows the result after 21 days of treatment. The patient concluded that the level of irritation and itching was significantly bettered using the gel containing K. africana and brine compared to his experience with products only containing brine. This patient describes positive effects after the first 3 times of application. This example is representative for all the conducted tests in this group of patients.
Example 2
A composition of the invention in the form of a cream was prepared The cream comprised :
brine 50 %w/w
an extract of K. africana 5 %w/w
octyldodecyl stearate 10 %w/w
cetyl alcohol 8 %w/w
glycerine 4.2 %w/w
dicaprylyl carbonate 2.5 %w/w
lauryl polyglucose 2 %w/w
cera alba 2 %w/w
PEG-50 Shea butter 1.25 %w/w
glycerol stearate 1 %w/w
PEG-75 Stearate 1 %w/w
ceteth-20 1 %w/w
steareth-20 1 %w/w
polyg lyce ry 1- 2 d i polyhyd roxystea rate 0.5 %w/w
tocopherol 0.15 %w/w
allantoin 0.13 %w/w
water balance.
A typical way of using the cream containing K. africana and brine: The product was applied on the irritated skin 2-3 times per day or as needed. Compared to products only containing brine the test on patients conclude, that the combination of K. africana and brine gives a significant healing effect. The itching stops after 1-2 applications and this effect continued as long as the product was applied.
Claims
P A T E N T C L A I M S
I. A dressing product comprising a backing layer and an active ingredient layer comprising an extract of Kigelia africana, which active ingredient layer is coated or adhered to the backing layer.
2. The dressing product according to claim 1, wherein the active ingredient layer comprises a hydrocolloid adhesive.
3. The dressing product according to claim 1 or 2, wherein the backing layer is a polymer film.
4. A method of producing a dressing product according to any one of claims 1 to 3, the method comprising the steps of:
a) providing a backing layer;
b) applying a hot-melt hydrocolloid adhesive in a liquid form to the backing layer;
c) allowing the liquid hydrocolloid adhesive to solidify;
d) providing a Kigelia africana extract; and
e) spraying the K. africana extract onto the backing layer and/or to the solidified hydrocolloid adhesive.
5. The method according to claim 4, wherein piezoelectric ink-jet technology is employed in step e).
6. The method according to claim 4 or 5, wherein steps b) to e) are repeated.
7. The method according to any one of claims 4 to 6, wherein the extract comprises a volatile solvent, and the method further comprises the step of allowing the volatile solvent to evaporate.
8. The method according to any one of claims 4 to 7 further comprising the step of allowing the active ingredient to diffuse into the hydrocolloid adhesive.
9. A dressing product obtainable in a method according to any one of claims 4 to 8.
10. The dressing product according to any one of claims 1 to 3 or 9 contained in a carrier system comprising a foil member supporting the dressing product and a cover member covering the surface of hydrocolloid adhesive.
II. The dressing product according to claim 10, wherein the foil mem- ber and/or the cover member is paper or a polymer film.
12. The dressing product according to claim 10 or 11, wherein the cover member is siliconised.
13. A cosmetic or medical composition for topical application on the skin of a subject, which composition comprises:
brine 40 - 80 %w/w
an extract of Kigelia africana 2 - 15 %w/w
one or more excipients 5 - 50 %w/w
water balance
which excipients are selected from emulsifiers, suspending agents, gel- ling agents, binders, fillers, surfactants, anti-oxidants, preservatives, emollients, humectants, moisturisers, natural oils, UV-absorbers, sunscreens, and thickeners.
14. The cosmetic or medical composition according to claim 13, wherein the cosmetic or medical composition is a cream, gel, ointment, lotion or paste.
15. The cosmetic or medical composition according to claim 13 or 14, wherein the cosmetic or medical composition is a cream comprising :
brine 40 - 60 %w/w
an extract of K. africana 2 - 8 %w/w
one or more excipients 30 - 40 %w/w
water balance.
16. The cosmetic or medical composition according to claim 15, wherein the cosmetic or medical composition is a cream comprising :
brine 50 %w/w
an extract of K. africana 5 %w/w
octyldodecyl stearate 10 %w/w
cetyl alcohol 8 %w/w
glycerine 4.2 %w/w
dicaprylyl carbonate 2.5 %w/w
lauryl polyglucose 2 %w/w
cera alba 2 %w/w
PEG-50 Shea butter 1.25 %w/w
glycerol stearate 1 %w/w
PEG-75 Stearate 1 %w/w
ceteth-20 1 %w/w
steareth-20 1 %w/w
polyglyceryl-2 dipolyhydroxystearate 0.5 %w/w
tocopherol 0.15 %w/w
allantoin 0.13 %w/w
water balance.
17. The cosmetic or medical composition according to claim 13 or 14, wherein the cosmetic or medical composition is a gel comprising :
brine 60 - 80 %w/w
an extract of K. africana 5 - 15 %w/w
one or more excipients 5 - 15 %w/w
water balance,
wherein the excipients comprise a gelling agent.
18. The cosmetic or medical composition according to claim 17, wherein the cosmetic or medical composition is a gel comprising :
brine 70 %w/w
an extract of K. africana 10 %w/w
glycerin 5 %w/w
propylene glycol 2 %w/w
xanthan gum 1 %w/w
water balance.
19. The dressing product according to any one of claims 1 to 3 or 9 to 12, or the composition according to any one of claims 13 to 18 for use in the treatment of skin damages, diseases and conditions.
20. The dressing product according to claim 19, or the composition ac- cording to claim 19, wherein the disease or condition is psoriasis, eczemas, dermatitis or acne.
21. The dressing product according to any one of claims 1 to 3 or 9 to 12, or the composition according to any one of claims 13 to 18 for cosmetic use.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/DK2012/050280 WO2014015874A1 (en) | 2012-07-25 | 2012-07-25 | A dressing product and a cosmetic or medical composition with kigelia africana |
EP12881977.8A EP2877191A4 (en) | 2012-07-25 | 2012-07-25 | A dressing product and a cosmetic or medical composition with kigelia africana |
PCT/DK2013/050253 WO2014015881A2 (en) | 2012-07-25 | 2013-07-25 | A cosmetic or medical composition with kigelia africana |
EP13747340.1A EP2877250A2 (en) | 2012-07-25 | 2013-07-25 | A cosmetic or medical composition with kigelia africana |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/DK2012/050280 WO2014015874A1 (en) | 2012-07-25 | 2012-07-25 | A dressing product and a cosmetic or medical composition with kigelia africana |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014015874A1 true WO2014015874A1 (en) | 2014-01-30 |
Family
ID=48948991
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2012/050280 WO2014015874A1 (en) | 2012-07-25 | 2012-07-25 | A dressing product and a cosmetic or medical composition with kigelia africana |
PCT/DK2013/050253 WO2014015881A2 (en) | 2012-07-25 | 2013-07-25 | A cosmetic or medical composition with kigelia africana |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2013/050253 WO2014015881A2 (en) | 2012-07-25 | 2013-07-25 | A cosmetic or medical composition with kigelia africana |
Country Status (2)
Country | Link |
---|---|
EP (2) | EP2877191A4 (en) |
WO (2) | WO2014015874A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108210417A (en) * | 2018-02-02 | 2018-06-29 | 广州市聚吉科绿色化学共性技术研究院有限公司 | A kind of oil-control composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020176874A1 (en) * | 1998-07-10 | 2002-11-28 | Christian Dampeirou | Cosmetic compositions with high viscosity for female breast care containing rigelia extract |
WO2006002443A1 (en) * | 2004-06-24 | 2006-01-05 | Rudolf Karl Schleipfer | Pharmaceutical or cosmetic preparation based on kigelia africana |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW10292A1 (en) | 1992-11-02 | 1993-03-24 | Keith Bruce Duguid | Sausage tree(kigelia africana)fruit extract skin cream |
FR2759910B1 (en) | 1997-02-24 | 1999-12-03 | Greentech Sa | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITIONS FOR STRENGTHENING THE BUST, STIMULATING THE HAIR SYSTEM AND INHIBITION OR HAIRY SYSTEM, CONTAINING KIGELIA AFRICANA EXTRACTS |
ATE375772T1 (en) * | 2000-07-18 | 2007-11-15 | Coloplast As | WOUND DRESSING |
US6923982B2 (en) * | 2000-08-16 | 2005-08-02 | Scapa North America | Calendered hydrocolloid dressing |
US8728445B2 (en) * | 2001-05-01 | 2014-05-20 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Sciences | Hydrogel Compositions |
CN101380258B (en) * | 2001-11-23 | 2013-09-18 | 科洛普拉斯特公司 | A wound dressing |
DE10200490A1 (en) * | 2002-01-04 | 2003-07-10 | Knoell Hans Forschung Ev | Selective cyclooxygenase inhibitors, useful e.g. for treating inflammation, Alzheimer's disease, Parkinson's disease or arthritis, comprising Kigelia africana fruit or its extract |
HUP0202391A2 (en) * | 2002-07-19 | 2005-04-28 | János Shomer | Sea salt in form gel |
WO2005007071A2 (en) * | 2003-07-15 | 2005-01-27 | Intercosma Ltd. | Skin formulation |
EP1720508A1 (en) * | 2003-11-28 | 2006-11-15 | Coloplast A/S | An adhesive patch |
-
2012
- 2012-07-25 EP EP12881977.8A patent/EP2877191A4/en not_active Withdrawn
- 2012-07-25 WO PCT/DK2012/050280 patent/WO2014015874A1/en active Application Filing
-
2013
- 2013-07-25 WO PCT/DK2013/050253 patent/WO2014015881A2/en active Application Filing
- 2013-07-25 EP EP13747340.1A patent/EP2877250A2/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020176874A1 (en) * | 1998-07-10 | 2002-11-28 | Christian Dampeirou | Cosmetic compositions with high viscosity for female breast care containing rigelia extract |
WO2006002443A1 (en) * | 2004-06-24 | 2006-01-05 | Rudolf Karl Schleipfer | Pharmaceutical or cosmetic preparation based on kigelia africana |
Non-Patent Citations (2)
Title |
---|
O'MAHONY, J.: "Transdermal Technology", PHARMACEUTICAL MANUFACTURING AND PACKING SOURCER, May 2009 (2009-05-01), XP055181957 * |
See also references of EP2877191A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108210417A (en) * | 2018-02-02 | 2018-06-29 | 广州市聚吉科绿色化学共性技术研究院有限公司 | A kind of oil-control composition |
Also Published As
Publication number | Publication date |
---|---|
EP2877250A2 (en) | 2015-06-03 |
EP2877191A4 (en) | 2016-04-27 |
EP2877191A1 (en) | 2015-06-03 |
WO2014015881A2 (en) | 2014-01-30 |
WO2014015881A3 (en) | 2014-11-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUT75288A (en) | Hydrophilic, hot-melt-type pressure-sensitive adhesive | |
EP2979685B1 (en) | Film forming complex, cosmetic composition comprising it and their use as peel-off film mask | |
US20140114231A1 (en) | Formulations and Compositions of Hydrophobic Extracts of Skin Tree | |
CN101336879A (en) | Art pumpkin extract and use as anti-corrosive bacteria inhibitor and anti acne agent in cosmetics | |
US20120141575A1 (en) | Collagen For Use In The Treatment Of Skin Diseases | |
CN107693381A (en) | A kind of bar cloth veneer film containing flexible nano-liposomes | |
WO2013126697A1 (en) | Transdermal compositions and methods for treating stretch marks | |
CN103919846A (en) | Hydrogel composition and preparation thereof | |
EP0962226B1 (en) | External preparations containing watercress extract | |
CN104666496B (en) | A kind of menthol ointment and its preparation technology | |
US8460700B2 (en) | First aid formulations of turmeric powder lavender essential oil and glycerin for dressing wounds | |
US20080145461A1 (en) | Formulation and method of making a topical pain relief composition | |
CN104983674A (en) | External use drug for quickly relieving itching, eliminating swelling and rash, and resisting mosquito and insect bites | |
TW200927156A (en) | Sprayable composition comprising extract of red vine leaves | |
KR101130993B1 (en) | Phase change hidrogel including pulp | |
KR20150086922A (en) | Composition for relieving skin irritation and moisturizing skin containing natural fermented pine leaf extract | |
WO2014015874A1 (en) | A dressing product and a cosmetic or medical composition with kigelia africana | |
CN103536961B (en) | Medical cold compress bandage and production method thereof | |
CN105363021A (en) | Gel for promoting wound healing | |
US20070148219A1 (en) | Liposomal Nanowater-Containing Patch-Type Nanodermal Gel for Transdermal Delivery and Method for Preparing the Same | |
CN109700601A (en) | A kind of hydrocolloid silicon dressing patch | |
JP2004059519A (en) | Skin cosmetic for thin figure | |
KR101648466B1 (en) | Cosmetic composition for improving skin | |
WO2021191811A1 (en) | A novel wound gel composition | |
KR20110060571A (en) | Powder adhered hanji hydrogel maskpack |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12881977 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012881977 Country of ref document: EP |